Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Filings indexed 1,617 across all filing types
Latest filing 2026-05-20 Major Shareholding Noti…
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2026_3164_20260608F17.pdf
Major Shareholding Notification Classification · 85% confidence The document is a listing of the company’s top ten shareholders by shareholding ratio, including details of spouse/minor holdings and inter-shareholder relationships. This is a disclosure of significant share ownership positions rather than a financial report or corporate announcement. It aligns with the Major Shareholding Notification category.
2026-05-20 Chinese
115年年報及股東會資料 — 2025_3164_20260608FE4.pdf
Annual Report Classification · 94% confidence The document is titled “2025 Annual Report,” includes the full range of annual report sections (letter to shareholders, corporate governance, financial statements, operations review, risk analysis, consolidated statements), and is over 200k characters long (not just an announcement). It is the actual comprehensive yearly report covering company activities and full financial performance. Therefore, it is an Annual Report. FY 2025
2026-05-20 English
115年年報及股東會資料 — 2025_3164_20260608F04.pdf
Annual Report Classification · 96% confidence The document is titled “一一四年度年報” (Annual Report for fiscal year 114) and contains a complete set of sections typical of a full annual report: letter to shareholders, detailed financial statements and analyses, corporate governance report, auditor information, capital and share structure, business overview, risk factors, and more. This is not an announcement of a report nor a presentation; it is the actual comprehensive yearly report. Therefore, it should be classified as an Annual Report (10-K). FY 2025
2026-05-20 Chinese
公告本公司115年第一季合併財務報告提報董事會
Regulatory Filings
2026-05-06 Chinese
115年04月內部人持股異動(事後)
Regulatory Filings
2026-05-05 Chinese
115年04月董事會成員及持股
Regulatory Filings
2026-05-05 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.